NCT05313074

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 311 (actual)
• Sponsor: National Cancer Institute, Thailand · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.

Detailed description

A total of 311 participants, including 107 patients with solid tumor and 204 healthy volunteers who received 2 doses of CoronaVac were recruited from National Cancer Institute of Thailand between 2020-2021. Blood samples were collected after second dose of CoronaVac for 15 days and the neutralizing antibody (NAb) titers were detected using live-virus neutralization.SARS-CoV-2 antibody positivity was detected in 77 (72%) patients and 199 (97.5%) healthy volunteers. Antibody positivity rate was lowest (67.2%) in patients who received chemotherapy, followed by patients with post-treatment (74.2%) and patients who planned to start treatment (91.7%). Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, heterologous or otherwise, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.

Conditions

• COVID-19
• Cancer

Interventions

Type	Name	Description
BIOLOGICAL	CoronaVac vaccine	An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.

Timeline

• Start date: 2021-03-23
• Primary completion: 2022-02-25
• Completion: 2022-02-25
• First posted: 2022-04-06
• Last updated: 2022-04-15

Locations

1 site across 1 country: Thailand